About Kures
Kures is a Healthcare company based in New York (United States) founded in 2015 by Andrew Kruegel, and was acquired by ATAI in July 2020. Opioid-based therapeutics for mood and depression disorders are developed. Kures has raised $4.24 million across 1 funding round from investors including ATAI. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its competitors include Alto Neuroscience, Supernus Pharmaceuticals and Cerecor; 2 of its 3 listed competitors have raised funding.
Company details
Kures was established in 2015 and is based in New York, United States. Therapeutics utilizing opioids are developed by the company to address mood and depression disorders within the biotechnology sector. Operations focus on research and development of these treatments, with Andrew Kruegel serving as co-founder. Activities are centered in the United States, targeting unmet needs in mental health therapeutics.
- Headquarters New York, United States
- Founders Andrew Kruegel
- Stage Acquired
- SectorsHealthcare
- Website kuresinc.com
- Acquired by ATAI (Jul 2020)
Funding Insights of Kures
Kures has successfully raised a total of $4.24M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.24 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.24M
- Total Rounds 1
- Last Round Series A — $4.24M
- First Round $4.24M
(Sep 2019)
All 1 funding rounds of Kures with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $4.24M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Kures
Kures has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ATAI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biopharmaceutical company accelerating innovative mental health treatments. | 2018 | atai.life | Munich, Germany |
Investor details for Kures
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kures
1 people are tracked at Kures (1 in leadership).
| Name | Role | Group |
|---|---|---|
Andrew Kruegel | Co-Founder | Leadership |
Complete people profiles for Kures
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kures
3 dated milestones of Kures across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Kures is founded.
- Funding First funding round of $4.2M.
- Exit Acquired by ATAI.
Competitors of Kures
Kures has 3 listed competitors in our database, 2 of them funded. They include Alto Neuroscience, Supernus Pharmaceuticals and Cerecor.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | ||
| cerecor.com | 2011 | Baltimore, United States | $45.2M | 20 | Therapeutics for immunological and neurological disorders are developed. |
Detailed competitors of Kures
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Kures (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kures
Complete news archive for Kures
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kures
Kures was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Kures is headquartered in New York, United States. It is registered at New York, New York, United States.
Kures is a funded company, having raised a total of $4.24M across 1 funding round to date. The company's 1st funding round was a Series A of $4.24M, raised on Sep 2019.
Kures was established in 2015 and is based in New York, United States. Therapeutics utilizing opioids are developed by the company to address mood and depression disorders within the biotechnology sector. Operations focus on research and development of these treatments, with Andrew Kruegel serving as co-founder. Activities are centered in the United States, targeting unmet needs in mental health therapeutics.
Kures's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Cerecor.
Kures has 1 investor. Key investors include ATAI.
Yes. Kures was acquired by ATAI in July 2020.